Key result
Trial protocol details planned IVUS evaluation of rosuvastatin for coronary atheroma regression.
Answers are grounded in this paper and cite their sources.
BACKGROUND: There have been few multicenter studies using intravascular ultrasound (IVUS) to assess the process of atherosclerosis in a Japanese population with hypercholesterolemia that is being treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for control of low-density lipoprotein-cholesterol. METHODS AND RESULTS: An open-label multicenter study is planned to evaluate with IVUS whether treatment with rosuvastatin for 76 weeks results in regression of coronary artery atheroma volume in patients who have coronary heart disease (CHD) and hypercholesterolemia. Sample size is 200 subjects with CHD who are to undergo percutaneous coronary intervention. The planned duration is between October 2005 and October 2008. CONCLUSIONS: The COSMOS study will be the first multicenter cardiovascular study in a Japanese population and may provide new evidence on the effects of rosuvastatin on the progression of coronary atherosclerotic lesions.
No takes yet. Share an insight, caveat, or question.
Takayama et al. (2007) studied Coronary heart disease and hypercholesterolemia (n=200). Rosuvastatin was evaluated on Regression of coronary artery atheroma volume evaluated with intravascular ultrasound. Rosuvastatin treatment for 76 weeks is planned to be evaluated using intravascular ultrasound for coronary atheroma regression in 200 Japanese patients with CHD (study protocol; no results reported).
Synapse has enriched 10 related papers. Consider them for comparative context: